Research map: DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

Back to the article

Papers in this map

  1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel · Hartmut Döhner · 2016 · 5984 citations · Cited by this paper
  2. Tumor budding and tumor-associated lymphocytic response as histopathological indicators of high-risk disease in head and neck cutaneous squamous cell carcinoma · 2026 · Related
  3. Acute Myeloid Leukemia · Hartmut Döhner · 2015 · 3453 citations · Cited by this paper
  4. Integrative transcriptomic and experimental analyses identifies SDF4 as an astrocyte-expressed regulator of glioma progression through PI3K-AKT signaling · 2026 · Related
  5. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia · Courtney Denton Dinardo · 2020 · 2931 citations · Cited by this paper
  6. Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells · 2026 · Related
  7. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia · Hagop M. Kantarjian · 2012 · 1195 citations · Cited by this paper
  8. Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards · 2026 · Related
  9. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts · Hervé Dombret · 2015 · 1171 citations · Cited by this paper
  10. Senescence-related immunosuppressive gene MFAP2 orchestrates stromal-immune crosstalk and immunotherapy resistance in gastric cancer · 2026 · Related
  11. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome · Barbara Deschler-Baier · 2012 · 215 citations · Cited by this paper
  12. The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study · 2026 · Related
  13. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML · Nicholas James Short · 2024 · 178 citations · Cited by this paper
  14. Despite improved overall stratification, the 9th edition stage IIIA category remains prognostically heterogeneous: insights from a T3N2a subgroup analysis · 2026 · Related
  15. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine · Hartmut Döhner · 2024 · 150 citations · Cited by this paper
  16. Characterisation of a novel p53 mutation (p53N263Tfs*7) associated with li-fraumeni syndrome · 2026 · Related
  17. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial · Michael Lübbert · 2019 · 108 citations · Cited by this paper
  18. Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models · 2026 · Related
  19. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60 · Daniel Aaron Pollyea · 2021 · 95 citations · Cited by this paper
  20. Trends in treatment and survival of stage IV non-squamous NSCLC from 2010 to 2022 · 2026 · Related
  21. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML · Jing Lü · 2025 · 54 citations · Cited by this paper
  22. Retinoids in hematology: a timely revival? · Marie‐Claude Geoffroy · 2021 · 52 citations · Cited by this paper
  23. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial · Michael Lübbert · 2023 · 41 citations · Cited by this paper
  24. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms · Naseema Gangat · 2025 · 32 citations · Cited by this paper
  25. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial · Domenico Russo · 2024 · 26 citations · Cited by this paper
  26. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML · Courtney Denton Dinardo · 2025 · 26 citations · Cited by this paper
  27. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation · Ruth Meier · 2022 · 22 citations · Cited by this paper
  28. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry · Jesse Marc Tettero · 2023 · 21 citations · Cited by this paper
  29. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex · Lu Wang · 2022 · 20 citations · Cited by this paper
  30. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial · Fabio Efficace · 2024 · 18 citations · Cited by this paper
  31. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐ Trans Retinoic Acid or Valproic Acid to Decitabine · Helena Bresser · 2024 · 7 citations · Cited by this paper
  32. Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial · Xinping Zhou · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)